The AIP model has previously been used by us and others for the successful testing of experimental therapies, such as the use of rapamycin [6], cyclosporine A [6], and blockade of the interferon-α/interleukin-33 axis [32]. This evidence concerns the gene IL33 and autoimmune pancreatitis.